At a glance
ClinicalIndex Comparison RecordPhase 2Active· 103 enrolled
Drug / intervention
Cisplatin +1 moredrug
Likely dose
Cisplatin 100 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Radiation and Cisplatin for Oropharyngeal Cancer. Active but no longer recruiting, targeting 103 participants across 14 sites.
Detailed Summary
The purpose of this study is to find out whether radiotherapy to some of the lymph node areas can be safely omitted to decrease side effects without increasing the risk of the tumour coming back.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOropharyngeal Cancer
CountriesCanada
Collaborators--
Timeline
Phase 2Active
201920202021202220232024202520262027
First PostedJan 2019
Enrollment StartJun 2019
Primary CompletionJun 2024
TodayJul 2026
Study CompletionDec 2026
First PostedJan 30, 2019
Enrollment StartJun 28, 2019
Primary CompletionJun 25, 2024
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 7.4 years ago
Interventions
Radiationradiation
35 fractions, 5/wk, 7 wks 70Gy/56Gy, or 35 fractions, 6/wk, 6 wks, 70Gy/56Gy, or 35 fractions, 5/wk, 7 wks OR 6/wk, 6 wks 70Gy/56Gy
Cisplatindrug
100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks